Bloomberg Intelligence cover image

Novo Undercuts Lilly’s Obesity Drug Price for Cash-Pay in US

Bloomberg Intelligence

00:00

Novo Nordisk Undercuts Lilly on Obesity Drugs

Paul asks Michael Shah about Novo's pricing move; Shah explains Novo's cash-pay pricing strategy and competition with Lilly.

Play episode from 02:01
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app